• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在体外对恶性疟原虫进行长时间暴露处理期间阿奇霉素抗疟活性增强。

Increased antimalarial activity of azithromycin during prolonged exposure of Plasmodium falciparum in vitro.

作者信息

Yeo A E, Rieckmann K H

机构信息

Army Malaria Research Unit, University of Sydney, NSW, Australia.

出版信息

Int J Parasitol. 1995 Apr;25(4):531-2. doi: 10.1016/0020-7519(94)00119-9.

DOI:10.1016/0020-7519(94)00119-9
PMID:7635629
Abstract

The minimum inhibitory concentration, MIC, of azithromycin was determined for 2 isolates of Plasmodium falciparum at 48 and 96 h. The MIC at 48 h for the K1 and FC isolates were 6.2 and 8.7 micrograms/ml, respectively. At 96 h, the MIC decreased to 0.08 microgram/ml for the K1 isolate and 0.04 microgram/ml for the FC isolate. The marked reduction in the MIC values between the first and second asexual erythrocytic cycles suggests that the drug acts slowly and that it may have to be used in combination with a faster acting drug.

摘要

测定了阿奇霉素对2株恶性疟原虫在48小时和96小时时的最低抑菌浓度(MIC)。K1株和FC株在48小时时的MIC分别为6.2微克/毫升和8.7微克/毫升。在96小时时,K1株的MIC降至0.08微克/毫升,FC株的MIC降至0.04微克/毫升。在第一个和第二个无性红细胞周期之间MIC值的显著降低表明该药物作用缓慢,可能必须与作用更快的药物联合使用。

相似文献

1
Increased antimalarial activity of azithromycin during prolonged exposure of Plasmodium falciparum in vitro.在体外对恶性疟原虫进行长时间暴露处理期间阿奇霉素抗疟活性增强。
Int J Parasitol. 1995 Apr;25(4):531-2. doi: 10.1016/0020-7519(94)00119-9.
2
Prolonged exposure of Plasmodium falciparum to ciprofloxacin increases anti-malarial activity.
J Parasitol. 1994 Feb;80(1):158-60.
3
Potentiation of the antimalarial activity of atovaquone by doxycycline against Plasmodium falciparum in vitro.多西环素增强阿托伐醌对恶性疟原虫的体外抗疟活性。
Parasitol Res. 1997;83(5):489-91. doi: 10.1007/s004360050285.
4
The in vitro antimalarial activity of chloramphenicol against Plasmodium falciparum.氯霉素对恶性疟原虫的体外抗疟活性。
Acta Trop. 1994 Feb;56(1):51-4. doi: 10.1016/0001-706x(94)90039-6.
5
In-vitro antimalarial activity of azithromycin against chloroquine sensitive and chloroquine resistant Plasmodium falciparum.阿奇霉素对氯喹敏感及氯喹耐药恶性疟原虫的体外抗疟活性
J Postgrad Med. 2001 Oct-Dec;47(4):240-3.
6
Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro.阿奇霉素或红霉素与抗疟药联合使用对耐多药恶性疟原虫的体外活性。
Acta Trop. 2006 Dec;100(3):185-91. doi: 10.1016/j.actatropica.2006.10.008. Epub 2006 Nov 28.
7
In vitro activity of Pheroid vesicles containing antibiotics against Plasmodium falciparum.含抗生素类脂囊泡对恶性疟原虫的体外活性。
J Antibiot (Tokyo). 2012 Dec;65(12):609-14. doi: 10.1038/ja.2012.89. Epub 2012 Oct 24.
8
susceptibility of Indian isolates to different antimalarial drugs & antibiotics.印度分离株对不同抗疟药物和抗生素的敏感性。
Indian J Med Res. 2017 Nov;146(5):622-628. doi: 10.4103/ijmr.IJMR_1688_15.
9
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.阿奇霉素、青蒿琥酯和奎宁联合使用的体外抗疟活性及其与临床结果的相关性。
Antimicrob Agents Chemother. 2007 Feb;51(2):651-6. doi: 10.1128/AAC.01023-06. Epub 2006 Nov 20.
10
Indirect inhibition by antibiotics of nucleotide and deoxynucleotide biosynthesis in Plasmodium falciparum.
Southeast Asian J Trop Med Public Health. 1998 Mar;29(1):24-6.

引用本文的文献

1
Chemo-proteomics in antimalarial target identification and engagement.抗疟药物靶标鉴定和结合的化学生物组学。
Med Res Rev. 2023 Nov;43(6):2303-2351. doi: 10.1002/med.21975. Epub 2023 May 26.
2
Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection.开发一种新型人CD147基因敲入的NSG小鼠模型以测试新型冠状病毒2型(SARS-CoV-2)病毒感染。
Cell Biosci. 2022 Jun 11;12(1):88. doi: 10.1186/s13578-022-00822-6.
3
Development of a Novel Human CD147 Knock-in NSG Mouse Model to Test SARS-CoV-2 Viral Infection.
开发一种新型人CD147基因敲入NSG小鼠模型以测试SARS-CoV-2病毒感染
Res Sq. 2022 Apr 20:rs.3.rs-1431484. doi: 10.21203/rs.3.rs-1431484/v1.
4
Development of a Novel Human CD147 Transgenic NSG Mouse Model to test SARS-CoV-2 Infection and Immune Responses.开发一种新型人类CD147转基因NSG小鼠模型以测试新型冠状病毒(SARS-CoV-2)感染及免疫反应
Res Sq. 2021 Apr 7:rs.3.rs-396257. doi: 10.21203/rs.3.rs-396257/v1.
5
Treatment of adults with acute uncomplicated malaria with azithromycin and chloroquine in India, Colombia, and Suriname.在印度、哥伦比亚和苏里南,用阿奇霉素和氯喹治疗患有急性非复杂性疟疾的成年人。
Res Rep Trop Med. 2017 Oct 13;8:85-104. doi: 10.2147/RRTM.S129741. eCollection 2017.
6
Identifying rapidly parasiticidal anti-malarial drugs using a simple and reliable in vitro parasite viability fast assay.使用一种简单可靠的体外寄生虫活力快速测定法来鉴定快速杀寄生虫的抗疟药物。
Malar J. 2015 Nov 5;14:441. doi: 10.1186/s12936-015-0962-2.
7
Preliminary pharmaceutical development of antimalarial-antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas.抗疟疾抗生素联合疗法作为疟疾流行地区转诊前儿科发热治疗方法的初步药物研发
Int J Pharm. 2014 Jul 1;468(1-2):55-63. doi: 10.1016/j.ijpharm.2014.04.023. Epub 2014 Apr 13.
8
Pharmaceutical development and optimization of azithromycin suppository for paediatric use.阿奇霉素栓剂的药学开发与优化及其在儿科的应用。
Int J Pharm. 2013 Jan 30;441(1-2):218-26. doi: 10.1016/j.ijpharm.2012.11.040. Epub 2012 Dec 3.
9
Development of NIRS method for quality control of drug combination artesunate-azithromycin for the treatment of severe malaria.发展一种近红外光谱法(NIRS)用于控制联合药物青蒿琥酯-阿奇霉素的质量,以治疗严重疟疾。
J Pharm Biomed Anal. 2012 Aug-Sep;67-68:10-5. doi: 10.1016/j.jpba.2012.04.009. Epub 2012 Apr 23.
10
In vitro and in vivo activity of solithromycin (CEM-101) against Plasmodium species.体外和体内研究索利霉素(CEM-101)抗疟原虫活性。
Antimicrob Agents Chemother. 2012 Feb;56(2):703-7. doi: 10.1128/AAC.05039-11. Epub 2011 Nov 14.